At this time, New York Oncology Hematology does not have access to acquire and administer the new COVID prophylaxis shot Evusheld for immunocompromised patients. We await further guidance from NYS and will keep our patients updated.

Clinical Trials & Research

PH3 Ate +Cabo Renal Carcinoma

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994)

Disease Types: Renal,&nbs

Available at: {clinical_trial_location backspace="7"}PH3 Ate +Cabo Renal Carcinoma, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}